Notice of Proposed Sale · 144
Septerna, Inc.
SEPNNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Septerna, Inc.
- Issuer CIK
- 0001984086
- SEC file number
- 001-42382
- Phone
- 650-338-3533
- Person for whose account securities are to be sold
- Third Rock Ventures V, L.P.
- Relationships to issuer
- 10% Stockholder
- Street
- 250 EAST GRAND AVENUE, SUITE 65
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 147,200 | 7,507,200.00 | 46,676,947 | 08/12/2026 | Nasdaq | Raymond James & Associates |
Broker / market maker — proposed row 1, entry 1
- Name
- Raymond James & Associates
- Street
- 880 Carillon Parkway
- City
- St. Petersburg
- State / country code
- FL
- Postal code
- 33716
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/07/2022 | Original Issuance | Septerna, Inc. | 6,215,591 | N | 11/07/2022 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/12/2026
- Signed
- Melissa Fisher, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Third Rock Ventures V, LP
- Plan adoption dates
- 03/26/2026
Company context
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.